Tempus Ai (NASDAQ: TEM) stock is seeing an explosive valuation surge in Tuesday’s trading thanks to a pair of catalysts. The healthcare software company’s share price was up 35.8% as of 3:15 p.m. ET, and had been up as much as 41.8% earlier in the day.
In a recently published disclosure filing, Congresswoman Nancy Pelosi showed that she had purchased call options for Tempus Ai stock. The healthcare artificial intelligence (AI) company’s share price is also getting a boost from a press release announcing the company’s new software platform.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »
As a member of Congress, Nancy Pelosi is required to submit filings that disclose her and her husband’s stock sales and purchases. Along those lines, the former House speaker’s most recent disclosure showed that she had purchased 50 call options for Tempus Ai stock. These options had a strike price of $20 per share, and the overall trade had a value between $50,000 and $100,000.
Pelosi makes frequent stock market moves and has generally recorded very strong performance with her trades. According to an analysis conducted by UnusualWhales, Pelosi recorded gains of 70.9% on her stock trades in 2024 — far exceeding the roughly 25% gain for the S&P 500 (SNPINDEX: ^GSPC) across the stretch. In response to market-beating performance for her trades, some investors have been paying close attention to Pelosi’s market moves and replicating her purchases and sales.
In addition to gains powered by Pelosi’s options purchase disclosure, Tempus Ai stock is also getting a boost from the rollout of its AI-powered olivia healthcare app. The software is designed to combine and organize a patient’s health data in a single source and use that information to generate care insights.
Tempus says that the software allows patients to connect electronic health record (EHR) data from over 1,000 healthcare systems and digital health devices. The app can then provide patients with timelines, summaries, and insights that can be used by healthcare teams.
Despite today’s explosive gains, Tempus Ai is up just 16% over the last year of trading, as of this writing. It’s also still down roughly 40% from the high it reached in November. The software specialist has a relatively short history as a publicly traded company, having just gone public this past June.
With the preliminary full-year results it published earlier this month, Tempus announced that it anticipates revenue to have grown 30% annually to reach $693 million in 2024. The rollout of its new software platform could help growth keep coming in strong in 2025.
Before you buy stock in Tempus Ai, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus Ai wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $843,960!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of January 21, 2025
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
